Companion Diagnostic Development

We Build. We Validate. We Deliver.

ResearchDx integrates and aligns IVD and biopharma development that simplifies, speeds and ensures delivery of your FDA-approved companion diagnostics on time.

We Are With You Every Step of the Way.


We Are With You Every Step of the Way.


No Multi-Partner Outsourcing.

Watch CDO Video

Latest News

Negative Gluten ID Test Results can ‘Rule Out’ Celiac Disease in High Risk Populations

Brief:  First degree relatives of individuals with celiac disease are at elevated risk for developing a similarly severe gluten intolerance disorder. However, a quick screening test for the genetic alterations responsible for encoding gluten recognition immune receptors can rule out celiac disease risk in these individuals. Developed by Targeted Genomics, the DNA-based, non-invasive Gluten ID […]

Read More

Blood-Based Biomarkers Discriminate IBS from IBD with High Degree of Certainty in Patients with Chronic Diarrhea

Brief: Two blood-based biomarkers, cytolethal distending toxin B (CdtB) and anti-vinculin, have been substantively linked with the occurrence of diarrhea-predominant forms of irritable bowel syndrome (IBS). As a result, an ELISA-based diagnostic test developed by Gemelli Biotech is now able to “rule-in” an IBS diagnosis while “ruling-out” irritable bowel disease (IBD) based on elevated biomarker […]

Read More